35+ Insightful Sessions

Day 1

Keynote
08:30 - 09:00
Tomorrow’s winner will prioritise innovation – and inspire the workforce
  • Nurture leaders that set challenging goals and inspire staff to perform
  • Learn how to improve employee productivity by encouraging intellectual curiosity
  • Facilitate internal cross collaboration in a matrixial environment

Merck Serono Co., Ltd Alexandre de Muralt Representative Director and President Merck Serono Co., Ltd

09:00 - 09:30
PANEL DISCUSSION: Turning RWD into a strategic asset leveraging a collaboration platform
  • With an unprecedented amount of data becoming available internally and externally, explore ways to best capture the required data to turn it into a strategic asset that generates meaningful insights for accelerated R&D innovation, market access and better patient engagement
  • Examine how to tackle key challenges the industry is facing for RWD usability
  • Share leading practices of building a collaborative network among the industry, leading medical institutions and academia around oncology, leveraging ‘DoubleJump™ Interchange’, a leading real-world data platform

Moderator: PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

09:30 - 10:00
AstraZeneca K.K. Keynote Address

Details to be revealed

AstraZeneca K.K. Stefan Woxström Representative Director and President AstraZeneca K.K.

09:30 - 10:00
Sandoz K.K. Keynote Address

Details to be revealed

Sandoz K.K. Jason Hoffe President and Representative Director Sandoz K.K.

09:30 - 10:00
MHLW (Ministry of Health, Labour and Welfare) Keynote Address
The turning point in pricing: Bridge the gap between drug prices and healthcare costs
  • Explore the road map for Japan’s drug pricing policy and, based on what kind of reforms the drug pricing model can be optimized
  • Understand how global government bodies aim to reduce healthcare costs but ensure the most valuable drugs continue to be distributed based on real evidence

Tokyo Medical & Dental University<br>The Ministry of Health, Labour and Welfare (1986 - 2000) Kazuo Kawahara Professor, Department of Health care management & planning Tokyo Medical & Dental University
The Ministry of Health, Labour and Welfare (1986 - 2000)

Commercial Roundtables
10:30 - 11:00
Design a data-driven strategy that enables evidence-based decision-making

Understand how to amplify your data resources to enable a genuine evolution of your commercial activities and smartly use the data you already have, rather than relentlessly focussing on acquiring more data

10:30 - 11:00
Unrivalled digital driven insight through a solid data insight

Learn how to introduce digital change for your customers to smoothly embrace and make it easier for decision making by creating a strong digital platform foundation

10:30 - 11:00
Meet customer needs to deliver excellence in each region

Discuss ways to build area specific regional formulary by thoroughly understanding the area, engage with local authorities to provide a dedicated approach

RWE Roundtables
Nurture future data leaders

Discuss how to tackle the shortage of talent andthe best ways to nurture young talent to secure their future within the data field

Harness the potential of RWE to build an effective corporate structure

Discuss the best way to deploy RWE in your company to enable effective management, education and cost savings

Expand disease registries by collaborating with academia

Discuss the role that pharma should take and the relationship with academia when increasing registries in new disease areas to maximize the results.

Commercial
RWE & Data
Section 1:

Prioritise your patients by rethinking your business model

Section 1:

Your data journey: Build a value-based healthcare model which ensures future sustainability and prosperity

10:30 - 11:00
Develop a distinctive launch strategy by learning lessons from rare disease
  • A case study on the challenges and solutions from the clinical trials stage through to the launch of an orphan drug
  • Learn about alternative treatments and creative ways to tackle unmet patient need

Amicus Therapeutics K.K. Kurt Helge Rimkus VP & General Manager Amicus Therapeutics K.K.

Co-presentation: Recognise that the optimal future of medical care requires working not just for patients, but with patients
  • Create a real partnership to ensure access is based on high quality data and the voice of patients
  • Demonstrate patient outcomes, by using data, to determine value both inside and beyond your company walls
  • Understand the most effective ways to capture patient needs and stories, including how information is gathered and treatments are selected

Pfizer Japan Inc. Yasuyuki Katayama Corporate Officer, Country Medical Director and Head of Medical Japan Pfizer Japan Inc.

Shinsuke Amano Executive Director Japan Federation of Cancer Patient Groups

10:30 - 11:00
Dr. Joy Commercial Session:

Details to be revealed

Dr Joy Speaker TBC Dr Joy

Utilise RWD/PRO technology to help patients
  • Learn about the future of Japan’s RWD situation and learnings from other countries
  • Learn from a Patient Reported Outcomes case study to add value to RWD
  • Real-life examples of how to utilize AI in RWD

IQVIA Solution Japan K.K. Nobutomo Matsui Senior Principal
Real World Insights
IQVIA Solution Japan K.K.

10:30 - 11:00
Create a drug sales and promotion model from a solid understanding of Japan’s drug pricing policy and outcome-based trends
  • (Comparing NICE endorsed medicine guidelines and QALY indices) Build a sales model in line with trends regarding ROI and the provision of high cost medicine In an era where ROI and safety are indices for choosing the right medicine, learn how to promote patient benefits other than just efficacy
  • In an era where ROI and safety are indices for choosing the right medicine, learn how to promote patient benefits other than just efficacy

GlaxoSmithKline K.K. Katsunori Ohyama Director, Severe asthma dedicated sales force GlaxoSmithKline K.K.

PANEL DISCUSSION: Create a value-based blueprint for your company
  • Explore why the patient’s lifetime medical record is a key tool for establishing a higher standard of medical care
  • Take a fresh look at dormant academia data, improving access to medical databases and building RWD infrastructure in order to visualise the patient journey
  • Hear an expert perspective on reconciling the Act of the Next Generation Medical Infrastructure and handling personal information to recognize the limits of prescription and connected data
  • Discuss how to use data to improve the quality of medical care to offer more value to patients

Eiko Shimizu Project Associate Professor, Graduate School of Pharmaceutical Sciences University of Tokyo

Kyoto University Hospital Genta Kato Associate professor, Solutions Center for Health Insurance Claims Kyoto University Hospital

Celgene Corporation Shinichi Nishiuma Executive Director, Head, Medical Affairs, Japan Celgene Corporation


Day 2

Commercial
RWE & Data
Section 2:

Innovate for systemic change: Reform your approach to meet elevated customer expectations and remove internal silos

Section 2:

Fit for purpose: Set higher RWE quality standards in order to bring clarity and confidence to decisions which engender stakeholder trust

10:30 - 11:00
Integrate your commercial functions to enable your organisation to meet elevated customer expectations
  • How to effectively recruit commercial talent in challenging Japan marketplace
  • How to retain critical commercial talent
  • How to export more Japanese talents to global commercial leadership roles

Bristol Myers Squibb KK Frank Henderson Japan Business Lead, Talent Workforce & Innovation, Talent Workforce & Innovation Bristol Myers Squibb KK

Back to basics: The kinds of real world data and their appropriate use
  • Understand the fundamental kind of data to know when to reconsider your plan
  • Explore how to use medical RWD in areas such as descriptive epidemiology, outcome research, PMS and HEOR

Koji Kawakami Koji Kawakami Professor and Chair, Graduate School of Medicine and Public Health Kyoto University

10:30 - 11:00
Improve your ROI with digital channels: Move from product acknowledgment to translating to sales
  • Examine new digital models which provide in-depth information via new channels
  • Create a campaign that acts quickly on changing customer insights and adapt your engagement plans in real-time
  • Accelerate digital interactions with your customer to increase ROI
The importance of access to data in informing clinical practice – from safety, efficacy and affordability to epidemiology
  • Explore how Medical Affairs can tackle the 5th hurdle (“informing clinical practice”) with data generation
  • Discover how MSD uses existing real-world and newly available databases to demonstrate value and create trust whilst addressing their limitations
  • The National Database (NDB): explore its potential, risks and limitations.
  • Integrity is vital: Develop a framework in co-operation with stakeholders in order to gain trust – and make good use of Medical Affairs' unbiased, scientific-based nature

MSD K.K. Daniel Junichiro Ruzicka Executive Director, Medical Affairs MSD K.K.

10:30 - 11:00
Pharma vs the rest of the world: An external view of our industry’s relative performance in becoming a trusted partner
  • A look at the optimum ways to meet service and efficiency challenges across multiple channels with in-house and external digital marketing sources
  • Close the digital gap: Provide tailored care around your customer
  • Specific learnings from technology and B2C companies that could advance pharma’s future communication strategy
Use Real World data for clinical development and safety validation post-market surveillance
  • Examine how to use Real World Data for clinical development
  • Learn about safety assessment using Real World Data - including MID-NET - for post-market pharmacovigilance

Pfizer R&D Japan Norisuke Kawai Senior Director, Biometrics and Data Management Pfizer R&D Japan

Pfizer R&D Japan Yosuke Fujii Statistician, Clinical Statistics Pfizer R&D Japan

10:30 - 11:00
UCB Commercial Session:

Details to be revealed

Promote the use of the disease registry system (patient registry) to contribute to clinical trials and research
  • Grasp the current state of academic data with an outline of the Clinical Innovation Network
  • Take a look at case studies of muscular disease to learn how the registry can be leveraged to promote clinical development
  • As the number of disease areas increases, understand the role pharma should play and how the disease registry can be expanded
  • Examine the disease registry in light of new pharmaceutical affairs law

National Center of Neurology and Psychiatry Harumasa Nakamura Chief of clinical trial support unit, Translational medical center National Center of Neurology and Psychiatry

Section 3:

Harness the data opportunity: Unlock the potential of commercial data to really understand physicians and patients

Section 3:

Redesign your go-to-market model: Ensure your commercial endeavours are well-informed by excellent use of RWE

10:30 - 11:00
Data-driven Customer Centricity: the Key to Increased Competitiveness
  • Grasp the value of data-driven customer centricity and to what extent can it contribute to increased competitiveness
  • Understand the building blocks of a data-driven customer centric strategy and how can it be implemented
  • Explore how advanced analytical techniques such as AI and Machine Learning can contribute to a more customer centric way of interaction between HCPs and pharma companies

Trilations Björn Van Loy Global head of Analytics & Innovation
Advanced analytics
Trilations

Co-presentation: Form a robust corporate structure, centered on RWE
  • Determine how each division should function and cooperate to create value for patients
  • Understand company needs alongside the latest RWD objectives in order to achieve efficient management, education and cost-reduction

Eli Lilly K.K. Ann C TANG Sr Manager, HO/HTA/RWE, MDU Japan Eli Lilly K.K.

Pfizer Japan Inc. Kanae Togo Senior Manager, Outcome & Evidence Group, Corporate Affairs, Health & Value Pfizer Japan Inc.

10:30 - 11:00
Big changes coming to Japanese pharma - myths and reality
  • Understand underlying issues and trends that will accelerate change in the Japanese pharma industry
  • Learn how to thrive in a worsening pricing and reimbursement environment. Explore implications of HTA, the regionalisation of healthcare and the importance of digital information supported by AI

Ludwig Kanzler Representative Hanegi Solutions

Pre-competition: Alignment for faster progress
  • Master the art of successful partnership-building for an efficient drug discovery database containing clinical research data
  • Locate overlapping processes to cut waste in the data collection phase
Section 4:

Prepare for the future: Fundamentally rethink your sales roles to create effective and trusted sales teams

Section 4:

Beyond the pill: Find opportunities to create new value in our evolving data environment

10:30 - 11:00
Consider the balance between using internal and external resources, for better adaptability
  • Underline the pros and cons of investing in a flexible external MR field force
  • The balance between internal investment and external risk: identify what can be outsourced and what cannot
  • How to train and motivate your external resources to bring in revenue

Gilead Sciences K.K. Tomoo Miyake Director Business Excellence & Operations Gilead Sciences K.K.

An improved pharma company reputation, brought about by mobile technology
  • The era of developing and selling medicine is over
  • Create a strategy for using mobile technology in pharma companies
  • Examine the hurdles to implementing advanced technology for the good of society

Chugai Pharmaceutical Co.,Ltd. Kotonari Aoki Department Manager, Real World Data Science Dept. Chugai Pharmaceutical Co.,Ltd.

10:30 - 11:00
AstraZeneca Commercial Session:

Details to be revealed

AstraZeneca K.K. Torsten Kanisch Executive Officer
Vice President, Commercial Excellence
AstraZeneca K.K.

Determine the best combination of digital tools and medicines to generate the greatest cancer treatment outcomes
  • Learn about digital tools which facilitate stronger patient-physician communication in order to improve the QOL of cancer patients
  • Explore how Novartis use these tools to improve continuous long term cancer treatments, following prognosis

Novartis Motoi Muraki Head of Market Access & Business Development Oncology Novartis

10:30 - 11:00
New life for older products – Breath in a declining mature asset
  • Conquer the business turnaround challenge of restoring profitability to a declining mature asset
  • Describe a new operating model which re-engages employees with new roles, responsibilities and training and fosters collaboration to stimulate sales
  • Back to profitable growth: How to develop and communicate a customer-centric winning strategy to your sales and account teams

Merck Serono Japan Anant Vailaya Head, Oncology Business Unit Merck Serono Japan

Keynote
08:30 - 09:00
Drive purpose-driven business model changes for 2025
  • Determine how to cope with new changes and challenges to enable new growth
  • Determine what should be outsourced and what should be nurtured internally
  • One size doesn’t fit all: Design your treatment program according to patient symptoms and needs through more personalised models

Celgene K.K. Satoru Noguchi President Celgene K.K.

09:00 - 09:30
LEO Pharma Keynote

LEO Pharma K.K. Stefan Sakurai President, Japan Representative Director LEO Pharma K.K.

09:30 - 10:00
PANEL DISCUSSION: Shift from competition to collaboration with other pharma firms
  • Identify Japanese pharma’s priorities and critical activities until 2025 to ensure effectiveness in your future plan
  • Reduce inefficiencies by ensuring individual teams are allocated joint responsibilities with competitors to focus on what’s best for customers
  • Learn from international experience: fill in the gaps and identify opportunities for strategic advantage

Boehringer Ingelheim Japan, Inc. (BIJI) Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. (BIJI)

Celgene K.K. Satoru Noguchi President Celgene K.K.

Sandoz K.K. Jason Hoffe President and Representative Director Sandoz K.K.

Keynote
08:30 - 09:00
Tomorrow’s winner will prioritise innovation – and inspire the workforce
  • Nurture leaders that set challenging goals and inspire staff to perform
  • Learn how to improve employee productivity by encouraging intellectual curiosity
  • Facilitate internal cross collaboration in a matrixial environment

Merck Serono Co., Ltd Alexandre de Muralt Representative Director and President Merck Serono Co., Ltd

09:00 - 09:30
PANEL DISCUSSION: Turning RWD into a strategic asset leveraging a collaboration platform
  • With an unprecedented amount of data becoming available internally and externally, explore ways to best capture the required data to turn it into a strategic asset that generates meaningful insights for accelerated R&D innovation, market access and better patient engagement
  • Examine how to tackle key challenges the industry is facing for RWD usability
  • Share leading practices of building a collaborative network among the industry, leading medical institutions and academia around oncology, leveraging ‘DoubleJump™ Interchange’, a leading real-world data platform

Moderator: PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

09:30 - 10:00
AstraZeneca K.K. Keynote Address

Details to be revealed

AstraZeneca K.K. Stefan Woxström Representative Director and President AstraZeneca K.K.

09:30 - 10:00
Sandoz K.K. Keynote Address

Details to be revealed

Sandoz K.K. Jason Hoffe President and Representative Director Sandoz K.K.

09:30 - 10:00
MHLW (Ministry of Health, Labour and Welfare) Keynote Address
The turning point in pricing: Bridge the gap between drug prices and healthcare costs
  • Explore the road map for Japan’s drug pricing policy and, based on what kind of reforms the drug pricing model can be optimized
  • Understand how global government bodies aim to reduce healthcare costs but ensure the most valuable drugs continue to be distributed based on real evidence

Tokyo Medical & Dental University<br>The Ministry of Health, Labour and Welfare (1986 - 2000) Kazuo Kawahara Professor, Department of Health care management & planning Tokyo Medical & Dental University
The Ministry of Health, Labour and Welfare (1986 - 2000)

Commercial Roundtables
10:30 - 11:00
Design a data-driven strategy that enables evidence-based decision-making

Understand how to amplify your data resources to enable a genuine evolution of your commercial activities and smartly use the data you already have, rather than relentlessly focussing on acquiring more data

10:30 - 11:00
Unrivalled digital driven insight through a solid data insight

Learn how to introduce digital change for your customers to smoothly embrace and make it easier for decision making by creating a strong digital platform foundation

10:30 - 11:00
Meet customer needs to deliver excellence in each region

Discuss ways to build area specific regional formulary by thoroughly understanding the area, engage with local authorities to provide a dedicated approach

RWE Roundtables
Nurture future data leaders

Discuss how to tackle the shortage of talent andthe best ways to nurture young talent to secure their future within the data field

Harness the potential of RWE to build an effective corporate structure

Discuss the best way to deploy RWE in your company to enable effective management, education and cost savings

Expand disease registries by collaborating with academia

Discuss the role that pharma should take and the relationship with academia when increasing registries in new disease areas to maximize the results.

Commercial
RWE & Data
Section 1:

Prioritise your patients by rethinking your business model

Section 1:

Your data journey: Build a value-based healthcare model which ensures future sustainability and prosperity

10:30 - 11:00
Develop a distinctive launch strategy by learning lessons from rare disease
  • A case study on the challenges and solutions from the clinical trials stage through to the launch of an orphan drug
  • Learn about alternative treatments and creative ways to tackle unmet patient need

Amicus Therapeutics K.K. Kurt Helge Rimkus VP & General Manager Amicus Therapeutics K.K.

Co-presentation: Recognise that the optimal future of medical care requires working not just for patients, but with patients
  • Create a real partnership to ensure access is based on high quality data and the voice of patients
  • Demonstrate patient outcomes, by using data, to determine value both inside and beyond your company walls
  • Understand the most effective ways to capture patient needs and stories, including how information is gathered and treatments are selected

Pfizer Japan Inc. Yasuyuki Katayama Corporate Officer, Country Medical Director and Head of Medical Japan Pfizer Japan Inc.

Shinsuke Amano Executive Director Japan Federation of Cancer Patient Groups

10:30 - 11:00
Dr. Joy Commercial Session:

Details to be revealed

Dr Joy Speaker TBC Dr Joy

Utilise RWD/PRO technology to help patients
  • Learn about the future of Japan’s RWD situation and learnings from other countries
  • Learn from a Patient Reported Outcomes case study to add value to RWD
  • Real-life examples of how to utilize AI in RWD

IQVIA Solution Japan K.K. Nobutomo Matsui Senior Principal
Real World Insights
IQVIA Solution Japan K.K.

10:30 - 11:00
Create a drug sales and promotion model from a solid understanding of Japan’s drug pricing policy and outcome-based trends
  • (Comparing NICE endorsed medicine guidelines and QALY indices) Build a sales model in line with trends regarding ROI and the provision of high cost medicine In an era where ROI and safety are indices for choosing the right medicine, learn how to promote patient benefits other than just efficacy
  • In an era where ROI and safety are indices for choosing the right medicine, learn how to promote patient benefits other than just efficacy

GlaxoSmithKline K.K. Katsunori Ohyama Director, Severe asthma dedicated sales force GlaxoSmithKline K.K.

PANEL DISCUSSION: Create a value-based blueprint for your company
  • Explore why the patient’s lifetime medical record is a key tool for establishing a higher standard of medical care
  • Take a fresh look at dormant academia data, improving access to medical databases and building RWD infrastructure in order to visualise the patient journey
  • Hear an expert perspective on reconciling the Act of the Next Generation Medical Infrastructure and handling personal information to recognize the limits of prescription and connected data
  • Discuss how to use data to improve the quality of medical care to offer more value to patients

Eiko Shimizu Project Associate Professor, Graduate School of Pharmaceutical Sciences University of Tokyo

Kyoto University Hospital Genta Kato Associate professor, Solutions Center for Health Insurance Claims Kyoto University Hospital

Celgene Corporation Shinichi Nishiuma Executive Director, Head, Medical Affairs, Japan Celgene Corporation

Commercial
RWE & Data
Section 2:

Innovate for systemic change: Reform your approach to meet elevated customer expectations and remove internal silos

Section 2:

Fit for purpose: Set higher RWE quality standards in order to bring clarity and confidence to decisions which engender stakeholder trust

10:30 - 11:00
Integrate your commercial functions to enable your organisation to meet elevated customer expectations
  • How to effectively recruit commercial talent in challenging Japan marketplace
  • How to retain critical commercial talent
  • How to export more Japanese talents to global commercial leadership roles

Bristol Myers Squibb KK Frank Henderson Japan Business Lead, Talent Workforce & Innovation, Talent Workforce & Innovation Bristol Myers Squibb KK

Back to basics: The kinds of real world data and their appropriate use
  • Understand the fundamental kind of data to know when to reconsider your plan
  • Explore how to use medical RWD in areas such as descriptive epidemiology, outcome research, PMS and HEOR

Koji Kawakami Koji Kawakami Professor and Chair, Graduate School of Medicine and Public Health Kyoto University

10:30 - 11:00
Improve your ROI with digital channels: Move from product acknowledgment to translating to sales
  • Examine new digital models which provide in-depth information via new channels
  • Create a campaign that acts quickly on changing customer insights and adapt your engagement plans in real-time
  • Accelerate digital interactions with your customer to increase ROI
The importance of access to data in informing clinical practice – from safety, efficacy and affordability to epidemiology
  • Explore how Medical Affairs can tackle the 5th hurdle (“informing clinical practice”) with data generation
  • Discover how MSD uses existing real-world and newly available databases to demonstrate value and create trust whilst addressing their limitations
  • The National Database (NDB): explore its potential, risks and limitations.
  • Integrity is vital: Develop a framework in co-operation with stakeholders in order to gain trust – and make good use of Medical Affairs' unbiased, scientific-based nature

MSD K.K. Daniel Junichiro Ruzicka Executive Director, Medical Affairs MSD K.K.

10:30 - 11:00
Pharma vs the rest of the world: An external view of our industry’s relative performance in becoming a trusted partner
  • A look at the optimum ways to meet service and efficiency challenges across multiple channels with in-house and external digital marketing sources
  • Close the digital gap: Provide tailored care around your customer
  • Specific learnings from technology and B2C companies that could advance pharma’s future communication strategy
Use Real World data for clinical development and safety validation post-market surveillance
  • Examine how to use Real World Data for clinical development
  • Learn about safety assessment using Real World Data - including MID-NET - for post-market pharmacovigilance

Pfizer R&D Japan Norisuke Kawai Senior Director, Biometrics and Data Management Pfizer R&D Japan

Pfizer R&D Japan Yosuke Fujii Statistician, Clinical Statistics Pfizer R&D Japan

10:30 - 11:00
UCB Commercial Session:

Details to be revealed

Promote the use of the disease registry system (patient registry) to contribute to clinical trials and research
  • Grasp the current state of academic data with an outline of the Clinical Innovation Network
  • Take a look at case studies of muscular disease to learn how the registry can be leveraged to promote clinical development
  • As the number of disease areas increases, understand the role pharma should play and how the disease registry can be expanded
  • Examine the disease registry in light of new pharmaceutical affairs law

National Center of Neurology and Psychiatry Harumasa Nakamura Chief of clinical trial support unit, Translational medical center National Center of Neurology and Psychiatry

Section 3:

Harness the data opportunity: Unlock the potential of commercial data to really understand physicians and patients

Section 3:

Redesign your go-to-market model: Ensure your commercial endeavours are well-informed by excellent use of RWE

10:30 - 11:00
Data-driven Customer Centricity: the Key to Increased Competitiveness
  • Grasp the value of data-driven customer centricity and to what extent can it contribute to increased competitiveness
  • Understand the building blocks of a data-driven customer centric strategy and how can it be implemented
  • Explore how advanced analytical techniques such as AI and Machine Learning can contribute to a more customer centric way of interaction between HCPs and pharma companies

Trilations Björn Van Loy Global head of Analytics & Innovation
Advanced analytics
Trilations

Co-presentation: Form a robust corporate structure, centered on RWE
  • Determine how each division should function and cooperate to create value for patients
  • Understand company needs alongside the latest RWD objectives in order to achieve efficient management, education and cost-reduction

Eli Lilly K.K. Ann C TANG Sr Manager, HO/HTA/RWE, MDU Japan Eli Lilly K.K.

Pfizer Japan Inc. Kanae Togo Senior Manager, Outcome & Evidence Group, Corporate Affairs, Health & Value Pfizer Japan Inc.

10:30 - 11:00
Big changes coming to Japanese pharma - myths and reality
  • Understand underlying issues and trends that will accelerate change in the Japanese pharma industry
  • Learn how to thrive in a worsening pricing and reimbursement environment. Explore implications of HTA, the regionalisation of healthcare and the importance of digital information supported by AI

Ludwig Kanzler Representative Hanegi Solutions

Pre-competition: Alignment for faster progress
  • Master the art of successful partnership-building for an efficient drug discovery database containing clinical research data
  • Locate overlapping processes to cut waste in the data collection phase
Section 4:

Prepare for the future: Fundamentally rethink your sales roles to create effective and trusted sales teams

Section 4:

Beyond the pill: Find opportunities to create new value in our evolving data environment

10:30 - 11:00
Consider the balance between using internal and external resources, for better adaptability
  • Underline the pros and cons of investing in a flexible external MR field force
  • The balance between internal investment and external risk: identify what can be outsourced and what cannot
  • How to train and motivate your external resources to bring in revenue

Gilead Sciences K.K. Tomoo Miyake Director Business Excellence & Operations Gilead Sciences K.K.

An improved pharma company reputation, brought about by mobile technology
  • The era of developing and selling medicine is over
  • Create a strategy for using mobile technology in pharma companies
  • Examine the hurdles to implementing advanced technology for the good of society

Chugai Pharmaceutical Co.,Ltd. Kotonari Aoki Department Manager, Real World Data Science Dept. Chugai Pharmaceutical Co.,Ltd.

10:30 - 11:00
AstraZeneca Commercial Session:

Details to be revealed

AstraZeneca K.K. Torsten Kanisch Executive Officer
Vice President, Commercial Excellence
AstraZeneca K.K.

Determine the best combination of digital tools and medicines to generate the greatest cancer treatment outcomes
  • Learn about digital tools which facilitate stronger patient-physician communication in order to improve the QOL of cancer patients
  • Explore how Novartis use these tools to improve continuous long term cancer treatments, following prognosis

Novartis Motoi Muraki Head of Market Access & Business Development Oncology Novartis

10:30 - 11:00
New life for older products – Breath in a declining mature asset
  • Conquer the business turnaround challenge of restoring profitability to a declining mature asset
  • Describe a new operating model which re-engages employees with new roles, responsibilities and training and fosters collaboration to stimulate sales
  • Back to profitable growth: How to develop and communicate a customer-centric winning strategy to your sales and account teams

Merck Serono Japan Anant Vailaya Head, Oncology Business Unit Merck Serono Japan

Keynote
08:30 - 09:00
Drive purpose-driven business model changes for 2025
  • Determine how to cope with new changes and challenges to enable new growth
  • Determine what should be outsourced and what should be nurtured internally
  • One size doesn’t fit all: Design your treatment program according to patient symptoms and needs through more personalised models

Celgene K.K. Satoru Noguchi President Celgene K.K.

09:00 - 09:30
LEO Pharma Keynote

LEO Pharma K.K. Stefan Sakurai President, Japan Representative Director LEO Pharma K.K.

09:30 - 10:00
PANEL DISCUSSION: Shift from competition to collaboration with other pharma firms
  • Identify Japanese pharma’s priorities and critical activities until 2025 to ensure effectiveness in your future plan
  • Reduce inefficiencies by ensuring individual teams are allocated joint responsibilities with competitors to focus on what’s best for customers
  • Learn from international experience: fill in the gaps and identify opportunities for strategic advantage

Boehringer Ingelheim Japan, Inc. (BIJI) Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. (BIJI)

Celgene K.K. Satoru Noguchi President Celgene K.K.

Sandoz K.K. Jason Hoffe President and Representative Director Sandoz K.K.